Epigenetic BET inhibitor apabetalone counters inflammatory and fibrotic processes in activated cardiac fibroblasts providing insight into reduced hospitalizations for heart failure in BETonMACE trial

Back

ESC Professional Premium Access

Epigenetic BET inhibitor apabetalone counters inflammatory and fibrotic processes in activated cardiac fibroblasts providing insight into reduced hospitalizations for heart failure in BETonMACE trial

Session: Epigenetic targets in cardiovascular disease

Topic: Fibrosis

Speaker: Doctor E. Kulikowski (Calgary, CA)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Ewelina Kulikowski

Calgary (Canada)

1 presentation

0 follower

5 more presentations in this session

Targeting BRD4-HK2 reverses the meta-inflammatory shift in perivascular adipose tissue and rescues cardiometabolic vascular dysfunction.

Speaker: Assistant Professor A. Mengozzi (Pisa, IT)

Targeting the histone methyltransferase SETD7 rescues diabetes-induced impairment of angiogenic response by transcriptional repression of semaphorin 3G

Speaker: Doctor S. Mohammed (Zurich, CH)

Chromatin remodeling by the histone methyltransferase SETD2 drives cardiometabolic heart failure with preserved ejection fraction

Speaker: Doctor S. Costantino (Zurich, CH)

The BET inhibitor Apabetalone protects against heart failure with preserved ejection fraction by suppressing myocardial inflammation

Speaker: Doctor E. Gorica (Zurich, CH)

RBM20 promotes doxorubicin-induced cardiotoxicity by Atp6v0a1 alternative splicing

Speaker: Doctor Z. Qiu (Shanghai, CN)

Access the full session

Epigenetic targets in cardiovascular disease

Speakers: Doctor E. Kulikowski, Assistant Professor A. Mengozzi, Doctor S. Mohammed, Doctor S. Costantino, Doctor E. Gorica...

Access

Video

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources